

## DAFTAR PUSTAKA

1. Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. *Cold Spring Harb. Perspect.Med.* 2015,1;5(5):a017822.
2. WHO. *Global tuberculosis report 2018*. Geneva: World Health Organization. 2018. Available at: <http://www.who.int>. [Accessed on 23 Des 2021]
3. KEMENKES RI. *Infodatin: Tuberkulosis Temukan Obati Sampai Sembuh*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI. 2018. Available at: <https://pusdatin.kemkes.go.id>. [Accessed on 16 Feb 2022]
4. Jeong YJ, Lee KS, Yim JJ. The diagnosis of pulmonary tuberculosis: *Precis Future Med.* 2017;1(2):77-87.
5. Hamidah RW, Made MN, Soedarsono S. Risk factors of latent tuberculosis infection in healthcare workers at hospitals in jember city indonesia. *Afr.J.Infect.Dis.* 2021;15(1):34-40.
6. Kothari H, Keshava S, Vatsyayan R, et al. Role of tissue factor in *Mycobacterium tuberculosis*-induced inflammation and disease pathogenesis. *PLoS One.* 2014;9(12):e114141.
7. Lasierra-Cirujeda J, Coronel P, Aza PMJ, et al. Stress/inflammation and pai-1 as stellar processes in the aging and associated pathologies. *Integr Mol Med.* 2018; 5(1): 1-2.
8. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. *Cardiovasc Ther.* 2010;28(5):e72-91.

9. Gleeerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. *Angiology*. 1995;46(8):715-8.
10. Eriksson P, Reynisdottir S, Lönnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. *Diabetologia*. 1998 ;41(1):65-71.
11. Smith LH, Coats SR, Qin H, et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor  $\alpha$  and estrogen receptor  $\beta$  in endothelial cells. *Circ Res*. 2004 ;95(3):269-75.
12. Widoyono MP. Penyakit Tropis Epidemiologi, Penularan, Pencegahan, dan Pemberantasannya. Jakarta ;Erlangga ; 2008.
13. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. *N Eng J Med*. 2002;347(23):1860-6.
14. Hauck, Fern R et al. "Identification and management of latent tuberculosis infection." *Am Fam Physician* vol. 79,10 (2009): 879-86.
15. Katial RK, Hershey J, Purohit-Seth T, et al. Cell-mediated immune response to tuberculosis antigens: comparison of skin testing and measurement of in vitro gamma interferon production in whole-blood culture. *Clin Diagn Lab*. 2001;8(2):339-45.
16. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. *Ann Rheum Dis*. 2002;62;ii54-8.
17. Van Crevel R, Ottenhoff TH, Van Der Meer JW. Innate immunity to *Mycobacterium tuberculosis*. *Clin Microbiol Rev*. 2002;15(2):294-309.

18. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. *Cell Host Microbe*. 2008 ;3(6):399-407.
19. Carranza C, Juárez E, Torres M, et al. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. *Am J Respir Crit*. 2006 ;173(2):238-45.
20. Cho SH, Tam SW, Demissie-Sanders S, et al. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. *J. Immunol*. 2000;165(6):3154-61.
21. Bernot D, Stalin J, Stocker P, et al. Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. *J Cell Sci*. 2011 124(8):1224-30.
22. Stewart CE, Nijmeh HS, Brightling CE. uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. *Am J Respir Cell Mol Biol*. 2006;35:503-11.
23. Margaglione M, Cappucci G, d'Addetta M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. *Arterioscler Thromb Vasc Biol*. 1998;18(4):562-7.
24. Yamamoto K, Takeshita K, Kojima T, et al. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. *Cardiovasc Res*. 2005;66(2):276-85.

25. Yasar Yildiz S, Kuru P, Toksoy Oner E, et al. Functional stability of plasminogen activator inhibitor-1. *Sci World J.* 2014; 8(1):1-8.
26. Khan SS. The Central Role of PAI-1 in COVID-19: Thrombosis and beyond. *Am J Respir Cell Mol.* 2021 ;65(3):238-40.
27. Vousden KA, Lundqvist T, Popovic B, et al. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. *Sci Rep.* 2019 ;9(1):1-2.
28. Kager LM, van der Windt GJ, Wieland CW, et al. Plasminogen activator inhibitor type I may contribute to transient, non-specific changes in immunity in the subacute phase of murine tuberculosis. *Microbes Infect.* 2012;14(9):748-55.
29. Koh GC, Schreiber MF, Bautista R, et al. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. *PloS one.* 2013 ;8(1):e54961.
30. Andrianto A, Rizkiawan R, Harsoyo PM. COVID-19 and Endothelial Dysfunction: Biomarkers and Potential Drug Mechanisms. *IJTID.* 2021;9(2):108-19.
31. Shitrit D, Izbicki G, Shitrit AB, et al. Normal D-dimer levels in patients with latent tuberculosis infection. *Blood Coagul.* 2005;16(1):85-7.
32. Kager LM, Blok DC, Lede IO, et al. Pulmonary tuberculosis induces a systemic hypercoagulable state. *J Infect.* 2015;70(4):324-34.

33. Nkansah C, Addai-Mensah O, Mensah K, et al. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana. PloS one. 2021;16(4):e0250090.
34. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. *Circ J.* 1995 ;91(7):1952-8.
35. Iskandar H, Polopadang J, Aman M. The level of plasminogen activator inhibitors 1 in asthma patients and correlation with lung function and dedree of asthma control. *Respirology.* 2018 ; 23: 93-94
36. Somodi S, Seres I, Lórinicz H, et al. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. *Int J Endocrinol.* 2018 ; 9(1):1-9
37. Kwaan HC, Lindholm PF. The central role of fibrinolytic response in COVID-19-a hematologist's perspective. *Int J Mol Sci.* 2021;22(3):1283.